Poster preliminary proof-of-concept studies

Poster 2A PharmaBarcelona – 2A Pharma presents poster at the World Vaccine Congress Europe

During the World Vaccine Congress Europe, we presented more details about our preliminary proof-of-concept studies and the development of the active vaccine against EpCAM+ cancers, which was developed using phage display and next generation sequencing to identify innovative epitopes that mimics the target protein.

The title of our poster is ”Pre-Clinical Proof-of-Concept of AAVLP-EpCAM Mimotope Vaccines in a Mouse Model with Human EpCAM Expressing CT26 Colon Cancer Cells.” To learn more, you can have a look at the Poster World Vaccine Congress Europe.

For more information, please contact us via our contact form.